Dhanuka Agritech · risk themes across the available quarters.
Bear-case history
Despite July improvement, large parts of the country remain rainfall-deficient. Q2 (July-September) is critical kharif season and management explicitly stated Q2 will also be difficult, with acreage potentially lower than last year.
Price increases attempted in April (due to West Asia geopolitical costs) could not be sustained from May onward as demand remained weak. Value and volume declines were nearly identical (~12.5-12.7%), indicating no pricing power.
The technical plant continues to burn cash with expected EBITDA loss of ~₹45 crore in FY27 despite achieving ₹26 crore Q1 revenue. Break-even remains elusive, creating ongoing drag on consolidated profitability.
A GST notice on biologicals (fertilizer category at 5% rate) is under legal review with Lakshmi Kumaran as consultant. Management expressed confidence but timeline for resolution was not provided.
Approvals for three bio-stimulant products are expected by end of Q4 FY26; any delay could impact Q1 FY27 sales, as peak season starts in July.
Early El Niño predictions could affect monsoon rains and farmer incomes, potentially reducing demand for agrochemicals in the kharif season.
Transition of Bayer products to Dhanuka's control involves regulatory and supply chain dependencies; any disruption could affect sales.
Inventory of imported molecules increased due to lower-than-expected sales, potentially leading to higher carrying costs or write-downs.